Search in:

Advanced search

Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 10

Submit an article Journal homepage

411

Views

CrossRef citations to date

Altmetric

Drug Evaluation

Arsenic trioxide

Mark R Litzow Mayo Clinic, Division of Hematology, 200 First Street SW, Rochester, MN 55905, USA +1 507 284 5362; +1 507 266 4972; [email protected]

, MD

Pages 1773-1785 | Published online: 21 Jun 2008

Cite this article
https://doi.org/10.1517/14656566.9.10.1773

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Richards S. Arsenic and old lace. In: The most popular plays of the American theatre: ten of Broadway's longest-running plays. Stein and Day/Scarborough House, New York; 1979. p. 452
Google Scholar
Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001;6(Suppl 2):3-10
PubMed Web of Science ®Google Scholar
Zhu J, Chen Z, Lallemand-Breitenbach V, De The H. How acute promyelocytic leukaemia revived arsenic. Nat Rev 2002;2(9):705-13
Google Scholar
Antman KH. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 2001;6(Suppl 2):1-2
PubMed Web of Science ®Google Scholar
Bonati A, Rizzoli V, Lunghi P. Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug. Curr Pharm Biotech 2006;7(6):397-405
PubMed Web of Science ®Google Scholar
Scheindlin S. The duplicitous nature of inorganic arsenic. Mol Intervent 2005;5(2):60-4
PubMedGoogle Scholar
Hillestad LK. Acute promyelocytic leukemia. Acta Med Scand 1957;159(3):189-94
PubMed Web of Science ®Google Scholar
Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33(4):451-8
PubMed Web of Science ®Google Scholar
Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1977;1(8010):549-50
PubMed Web of Science ®Google Scholar
Kakizuka A, Miller WH Jr, Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991;66(4):663-74
PubMed Web of Science ®Google Scholar
De The H, Chomienne C, Lanotte M, et al. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990;347(6293):558-61
PubMed Web of Science ®Google Scholar
Borrow J, Goddard AD, Sheer D, Solomon E. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990;249(4976):1577-80
PubMed Web of Science ®Google Scholar
Grimwade D, Biondi A, Mozziconacci MJ, et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Francais de Cytogenetique Hematologique, Groupe de Francais d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action ‘Molecular Cytogenetic Diagnosis in Haematological Malignancies’. Blood 2000;96(4):1297-308
PubMed Web of Science ®Google Scholar
Tallman MS, Brenner B, Serna Jdel, et al. Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom. Leuk Res 2005;29(3):347-51
PubMedGoogle Scholar
Bernard J, Weil M, Boiron M, et al. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood 1973;41(4):489-96
PubMed Web of Science ®Google Scholar
Zhou GB, Chen SJ, Chen Z. Acute promyelocytic leukemia: a model of molecular target based therapy. Hematology (Amsterdam) 2005;10(Suppl 1):270-80
PubMed Web of Science ®Google Scholar
Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72(2):567-72
PubMed Web of Science ®Google Scholar
Slack JL, Waxman S, Tricot G, et al. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. Oncologist 2002;7(Suppl 1):1-13
PubMedGoogle Scholar
De Botton S, Dombret H, Sanz M, et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1998;92(8):2712-8
PubMed Web of Science ®Google Scholar
Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89(9):3354-60
PubMed Web of Science ®Google Scholar
Fujisawa S, Ohno R, Shigeno K, et al. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide. Cancer Chemother Pharmacol 2007;59(4):485-93
PubMed Web of Science ®Google Scholar
Wang Z, Zhou J, Lu X, et al. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chem Res Toxicol 2004;17(1):95-103
PubMed Web of Science ®Google Scholar
Kumana CR, Au WY, Lee NS, et al. Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. Eur J Clin Pharmacol 2002;58(8):521-6
PubMed Web of Science ®Google Scholar
Au WY, Tam S, Fong BM, Kwong YL. Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia. Blood 2006;107(7):3012-3
PubMed Web of Science ®Google Scholar
Gazitt Y, Akay C. Arsenic trioxide: an anticancer missile with multiple warheads. Hematology (Amsterdam) 2005;10(3):205-13
PubMed Web of Science ®Google Scholar
Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997;89(9):3345-53
PubMed Web of Science ®Google Scholar
Hayakawa F, Privalsky M. Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell 2005;5(4):389-401
Google Scholar
Zhu J, Zhou J, Peres L, et al. A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell 2005;7(2):143-53
PubMed Web of Science ®Google Scholar
Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999;93(1):268-77
PubMed Web of Science ®Google Scholar
Davison K, Cote S, Mader S, Miller WH. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 2003;17(5):931-40
PubMed Web of Science ®Google Scholar
Yang CH, Kuo ML, Chen JC, Chen YC. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 1999;81(5):796-9
PubMed Web of Science ®Google Scholar
Halicka HD, Smolewski P, Darzynkiewicz Z, et al. Arsenic trioxide arrests cells early in mitosis leading to apoptosis. Cell Cycle (Georgetown TX) 2002;1(3):201-9
PubMed Web of Science ®Google Scholar
Woo SH, Park IC, Park MJ, et al. Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. Int J Oncol 2002;21(1):57-63
PubMed Web of Science ®Google Scholar
Yi J, Yang J, He R, et al. Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res 2004;64(1):108-16
PubMed Web of Science ®Google Scholar
Roboz G, Dias S, Lam G, et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000;96(4):1525-30
PubMed Web of Science ®Google Scholar
Davison K, Mann KK, Waxman S, Miller WH Jr. JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 2004;103(9):3496-502
PubMed Web of Science ®Google Scholar
Kajiguchi T, Yamamoto K, Hossain K, et al. Sustained activation of c-jun-terminal kinase (JNK) is closely related to arsenic trioxide-induced apoptosis in an acute myeloid leukemia (M2)-derived cell line, NKM-1. Leukemia 2003;17(11):2189-95
PubMed Web of Science ®Google Scholar
Lunghi P, Tabilio A, Lo-Coco F, et al. Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells. Leukemia 2005;19(2):234-44
PubMedGoogle Scholar
Lunghi P, Costanzo A, Levrero M, Bonati A. Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells. Blood 2004;104(2):519-25
PubMedGoogle Scholar
Giafis N, Katsoulidis E, Sassano A, et al. Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res 2006;66(13):6763-71
PubMed Web of Science ®Google Scholar
Tarkanyi I, Dudognon C, Hillion J, et al. Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death. Leukemia 2005;19(10):1806-11
PubMedGoogle Scholar
Glienke W, Chow K, Bauer N, Bergmann L. Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds. Leuk Lymphoma 2006;47(8):1629-38
PubMed Web of Science ®Google Scholar
Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996;88(3):1052-61
PubMed Web of Science ®Google Scholar
Zhang Y, Shen WL. Bcl-2 antisense oligodeoxynucleotide increases the sensitivity of leukemic cells to arsenic trioxide. Cell Biol Int 2003;27(12):953-8
PubMed Web of Science ®Google Scholar
Mathieu J, Besancon F. Arsenic trioxide represses NF-kappaB activation and increases apoptosis in ATRA-treated APL cells. Ann NY Acad Sci 2006;1090:203-8
PubMed Web of Science ®Google Scholar
Miller WH Jr, Schipper HM, Lee JS, et al. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62(14):3893-903
PubMed Web of Science ®Google Scholar
Hulai W, Haixiang S, Decheng B. Arsenic trioxide inhibits p-glycoprotein expression in multidrug-resistant human leukemia cells that overexpress the MDR1 gene. Chinese Med J 2003;116:1644-8
PubMedGoogle Scholar
Seo T, Urasaki Y, Takemura H, Ueda T. Arsenic trioxide circumvents multidrug resistance based on different mechanisms in human leukemia cell lines. Anticancer Res 2005;25(2A):991-8
PubMed Web of Science ®Google Scholar
Ling YH, Jiang JD, Holland JF, Perez-Soler R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol 2002;62(3):529-38
PubMed Web of Science ®Google Scholar
Tarrade A, Bastien J, Bruck N, et al. Retinoic acid and arsenic trioxide cooperate for apoptosis through phosphorylated RXR alpha. Oncogene 2005;24(14):2277-88
PubMedGoogle Scholar
Rojewski MT, Baldus C, Knauf W, et al. Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. Br J Haematol 2002;116(3):555-63
PubMed Web of Science ®Google Scholar
Zhu Q, Zhang J, Zhu H, et al. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood 2002;99(3):1014-22
PubMed Web of Science ®Google Scholar
Soignet S, Wang ZG, Nagy J. Dose ranging study of arsenic trioxide in advanced hematologic cancers: clinical pharmacokinetic and biological effects. Blood 1998;92:598A
Google Scholar
Sun HD, Ma L, Hu XC, Zhang TD. Ai-lin 1 treated 32 cases of acute promyelocytic leukemia. Chin J Integr Chin West Med 1992;12:170-1
Google Scholar
Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339(19):1341-8
PubMed Web of Science ®Google Scholar
Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19(18):3852-60
PubMed Web of Science ®Google Scholar
Camacho LH, Soignet SL, Chanel S, et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 2000;18(13):2620-5
PubMed Web of Science ®Google Scholar
Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006;17(1):131-4
PubMed Web of Science ®Google Scholar
Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006;107(9):3469-73
PubMed Web of Science ®Google Scholar
Wang G, Li W, Cui J, et al. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid. Hematol Oncol 2004;22(2):63-71
PubMed Web of Science ®Google Scholar
Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004;101(15):5328-35
PubMed Web of Science ®Google Scholar
Powell BL, Moser B, Stock W, et al. Effect of consolidation with arsenic trioxide (AS2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710. J Clin Oncol 2007;25(18S):2
Google Scholar
Au WY, Lie AK, Chim CS, et al. Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia. Ann Oncol 2003;14(5):752-7
PubMed Web of Science ®Google Scholar
Douer D, Hu W, Giralt S, et al. Arsenic trioxide (Trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Oncologist 2003;8(2):132-40
PubMed Web of Science ®Google Scholar
Kharfan-Dabaja MA, Abou Mourad YR, Fernandez HF, et al. Hematopoietic cell transplantation in acute promyelocytic leukemia: a comprehensive review. Biol Blood Marrow Transplant 2007;13(9):997-1004
PubMed Web of Science ®Google Scholar
Zheng X, Seshire A, Ruster B, et al. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica 2007;92(3):323-31
PubMed Web of Science ®Google Scholar
Kalmadi SR, Hussein MA. The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma. Acta Haematol 2006;116(1):1-7
PubMed Web of Science ®Google Scholar
Ravandi F. Arsenic trioxide: expanding roles for an ancient drug? Leukemia 2004;18(9):1457-9
PubMed Web of Science ®Google Scholar
Bahlis NJ, Mccafferty-Grad J, Jordan-Mcmurry I, et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002;8(12):3658-68
PubMed Web of Science ®Google Scholar
Hussein MA, Saleh M, Ravandi F, et al. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol 2004;125(4):470-6
PubMed Web of Science ®Google Scholar
Borad MJ, Swift R, Berenson JR. Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma. Leukemia 2005;19(1):154-6
PubMed Web of Science ®Google Scholar
Berenson JR, Boccia R, Siegel D, et al. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol 2006;135(2):174-83
PubMed Web of Science ®Google Scholar
Qazilbash MH, Saliba RM, Davis MS, et al. Arsenic trioxide with ascorbic acid and high-dose melphalan for autologous hematopoietic stem cell transplantation for multiple myeloma [abstract 3090]. Blood 2006;108:881A
Google Scholar
Campbell RA, Sanchez E, Steinberg JA, et al. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Br J Haematol 2007;138(4):467-78
PubMed Web of Science ®Google Scholar
Berenson JR, Matous J, Swift RA, et al. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 2007;13(6):1762-8
PubMed Web of Science ®Google Scholar
Lehmann S, Bengtzen S, Paul A, et al. Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance. Eur J Haematol 2001;66(6):357-64
PubMed Web of Science ®Google Scholar
Lu M, Levin J, Sulpice E, et al. Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines. Exp Hematol 1999;27(5):845-52
PubMed Web of Science ®Google Scholar
Lam HK, Li K, Chik KW, et al. Arsenic trioxide mediates intrinsic and extrinsic pathways of apoptosis and cell cycle arrest in acute megakaryocytic leukemia. Int J Oncol 2005;27(2):537-45
PubMedGoogle Scholar
Parmar S, Rundhaugen LM, Boehlke L, et al. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leukemia Res 2004;28(9):909-19
PubMed Web of Science ®Google Scholar
Douer D, Watkins K, Louie R, et al. Treatment of non-APL acute myelogenous leukemia with intravenous arsenic trioxide plus ascorbic acid [abstract 1959]. Blood 2006;108(11):554A
Google Scholar
Roboz G, Ritchie E, Allen-Bard S, et al. Arsenic trioxide is safe and effective in combination with low-dose Ara-c for the treatment of IPSS-2 myelodysplastic syndrome and poor-prognosis acute myeloid leukemia in elderly patients. Blood 2005;106:786A
Google Scholar
Bornhauser BC, Bonapace L, Lindholm D, et al. Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. Blood 2007;110(6):2084-91
PubMedGoogle Scholar
Hu XM, Hirano T, Oka K. Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells. Cancer Chemother Pharmacol 2003;51(2):119-26
PubMed Web of Science ®Google Scholar
Zhu XH, Shen YL, Jing YK, et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Nat Cancer Inst 1999;91(9):772-8
PubMed Web of Science ®Google Scholar
Litzow MR, Lee S, Bennett JM, et al. A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia. Haematologica 2006;91(8):1105-8
PubMedGoogle Scholar
Bazarbachi A, EL-Sabban ME, Nasr R, et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999;93(1):278-83
PubMed Web of Science ®Google Scholar
Ishitsuka K, Suzumiya J, Aoki M, et al. Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica 2007;92(5):719-20
PubMed Web of Science ®Google Scholar
Hermine O, Dombret H, Poupon J, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 2004;5(2):130-4
PubMedGoogle Scholar
Kerbauy DM, Lesnikov V, Abbasi N, et al. NF-kappa B and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood 2005;106(12):3917-25
PubMed Web of Science ®Google Scholar
Raza A, Buonamici S, Lisak L, et al. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leukemia Res 2004;28(8):791-803
PubMed Web of Science ®Google Scholar
Schiller GJ, Slack J, Hainsworth JD, et al. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol 2006;24(16):2456-64
PubMed Web of Science ®Google Scholar
Vey N, Bosly A, Guerci A, et al. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol 2006;24(16):2465-71
PubMed Web of Science ®Google Scholar
Au WY, Kumana CR, Liang R, Kwong YL. Preliminary experience of oral arsenic trioxide based therapy in the treatment of refractory mantle cell lymphoma [abstract 338]. Ann Oncol 2005;16:136
Google Scholar
Ravandi F, Van Besien K. Clinical activity of arsenic trioxide in Burkitt-like lymphoma. Leukemia 2003;17(1):271-2
PubMedGoogle Scholar
Nimmanapalli R, Bali P, O'Bryan E, et al. Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Cancer Res 2003;63(22):7950-8
PubMed Web of Science ®Google Scholar
La Rosee P, Johnson K, O'dwyer ME, Druker BJ. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 2002;30(7):729-37
PubMed Web of Science ®Google Scholar
Subbarayan PR, Lima M, Ardalan B: Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: a clinical experience. Acta Oncologica (Stockholm) 2007;46(4):557-61
PubMed Web of Science ®Google Scholar
Lin CC, Hsu C, Hsu CH, et al. Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Investig New Drugs 2007;25(1):77-84
PubMed Web of Science ®Google Scholar
Guo W, Tang XD, Tang S, Yang Y. Preliminary report of combination chemotherapy including arsenic trioxide for stage III osteosarcoma and Ewing sarcoma. Chinese J Surg 2006;44(12):805-8
PubMedGoogle Scholar
Vuky J, Yu R, Schwartz L, Motzer RJ. Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Investig New Drugs 2002;20(3):327-30
PubMed Web of Science ®Google Scholar
Huilgol NG. A phase I study to study arsenic trioxide with radiation and hyperthermia in advanced head and neck cancer. Int J Hyperthermia 2006;22(5):391-7
PubMed Web of Science ®Google Scholar
Beer TM, Tangen CM, Nichols CR, et al. Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer 2006;106(12):2624-9
PubMed Web of Science ®Google Scholar
Kim KB, Bedikian AY, Camacho LH, et al. A phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer 2005;104(8):1687-92
PubMed Web of Science ®Google Scholar
Cunha De Santis G, De Barros Tamarozzi M, Sousa RB, et al. Adhesion molecules and differentiation syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia. Haematologica 2007;92(12):1615-22
PubMedGoogle Scholar
Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 2003;21(19):3609-15
PubMed Web of Science ®Google Scholar
Ohnishi K, Yoshida H, Shigeno K, et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2000;133(11):881-5
PubMed Web of Science ®Google Scholar
Unnikrishnan D, Dutcher JP, Varshneya N, et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001;97(5):1514-6
PubMed Web of Science ®Google Scholar
Siu CW, Au WY, Yung C, et al. Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. Blood 2006;108(1):103-6
PubMed Web of Science ®Google Scholar
Chiang CE, Luk HN, Wang TM, Ding PY. Prolongation of cardiac repolarization by arsenic trioxide. Blood 2002;100(6):2249-52
PubMed Web of Science ®Google Scholar
Patel SP, Garcia-Manero G, Ferrajoli A, et al. Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia. Leukemia Res 2006;30(3):362-3
PubMedGoogle Scholar
Jones RL, Ewer MS. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Exp Rev Anticancer Ther 2006;6(9):1249-69
PubMed Web of Science ®Google Scholar
Trisenox injection. Micromedex, 2007. Available from: http://mdx2.mayo.edu/hcs/librarian/ND_PR/Main/SBK/2/PFPUI/FW5UMjA2eGpEHa/ND_PG/PRIH/CS/93FBB8/ND_T/HCS/ND_P/Main/DUPLICATIONSHIELDSYNC/6A6A6F/ND_B/HCS/PFActionId/hcs.common.RetrieveDocumentCommon/DocId/14810500/ContentSetId/58/SearchTerm/trisenox/SearchOption/BeginWith
Google Scholar
Mazumder DN, Das Gupta J, Santra A, et al. Chronic arsenic toxicity in west Bengal: the worst calamity in the world. J Indian Med Assoc 1998;96(1):4-7,18
PubMedGoogle Scholar
Au WY, Kumana CR, Kou M, et al. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood 2003;102(1):407-8
PubMed Web of Science ®Google Scholar
Mathews V, Desire S, George B, et al. Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity. Leukemia 2006;20(5):881-3
PubMed Web of Science ®Google Scholar
Lazo G, Kantarjian H, Estey E, et al. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the MD. Anderson experience. Cancer 2003;97(9):2218-24
PubMed Web of Science ®Google Scholar
Au WY, Kwong YL. Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: portents of an old scourge. J Am Acad Dermatol 2005;53(5):890-2
PubMed Web of Science ®Google Scholar
Nouri K, Ricotti CA, JR, Bouzari N, et al. The incidence of recurrent herpes simplex and herpes zoster infection during treatment with arsenic trioxide. J Drugs Dermatol 2006;5(2):182-5
PubMedGoogle Scholar
Patlolla AK, Tchounwou PB. Cytogenetic evaluation of arsenic trioxide toxicity in Sprague-Dawley rats. Mutation Res 2005;587(1-2):126-33
PubMed Web of Science ®Google Scholar
Au WY, Kumana CR, Lam CW, et al. Solid tumors subsequent to arsenic trioxide treatment for acute promyelocytic leukemia. Leukemia Res 2007;31(1):105-8
PubMed Web of Science ®Google Scholar
Verstovsek S, Estrov Z. Arsenic derivatives as therapeutic agents for hematologic malignancies. Leukemia Res 2004;28(9):901-3
PubMedGoogle Scholar
Lu DP, Qiu JY, Jiang B, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 2002;99(9):3136-43
PubMed Web of Science ®Google Scholar
Wu T, Zhao J, Jiang B, et al. Tetra-arsenic tetra-sulfide containing triple-agent regimen as the first line therapy for acute promyelocytic leukemia: expeditiously consecutive complete remission and improved disease-free survival [abstract 591]. Blood 2007;110:182a
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Arsenic trioxide

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Arsenic trioxide

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date